Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Albuminuria Reduction Trial in obese individuals without diabetes
NL-OMON50899Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in chronic kidney disease (CKD), obesity, sponsored by University Medical Center Groningen. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on NL-OMON50899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50899.